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ABSTRACT 
PURPOSE: To explore the hematological differences in African-American athletes with sickle 
cell trait (SCT) and healthy controls (CON) before preseason camp and the changes that occur 
after a full season. METHODS: Sixteen (n=8 SCT; n=8 position matched, CON) NCAA 
Division 1 athletes (12 football, 2 each women’s soccer and volleyball) had blood drawn before 
preseason camp, after and at the end of the season, and analyzed for Hb electrophoresis (Hb-A, 
Hb-A2, Hb-S, and Hb-F), complete blood count with differential, chemistry panel 26, and 
prothrombin time, activity and international normalized ratio (INR).  RESULTS:  Baseline total 
Hb was similar between SCT and CON (mean±SD; 14.2±1.3 vs. 14.1±0.9g/dL, resp; P=0.87), 
and as expected, Hb-A was lower and Hb-A2 and Hb-S were higher in SCT than CON (P<0.001 
for all).  Baseline neutrophils were higher (4.43±1.29 vs. 3.28±0.93cellsx10^3/mL, P<0.005) and 
lymphocytes tended to be lower (1.56±0.45 vs. 1.99±0.39cellsx10^3/mL; P=0.09) amongst SCT 
compared to CON, respectively.  Baseline amylase (99.4±25.4 vs. 72.9±18.8u/L; P=0.03), uric 
acid (6.8±1.7 vs. 5.5±0.8mg/dL; P=0.08), and creatinine (1.2±0.2 vs. 1.0±0.2mg/dL; P=0.07) 
were higher in SCT compared to CON.  All Hb measures in SCT were similar after camp 
compared to baseline (P>0.33 for all). Baseline and position adjusted change in neutrophils were 
similar between SCT and CON (mean, 95%CI; -0.09, -2.06 to 1.89 vs. 0.36, -1.61 to 
2.34cellsx10^3/mL, resp; P=0.77) from preseason to post-camp. Similarly, the adjusted change in 
lymphocytes was not different between SCT and CON (0.53, 0.01 to 1.05 vs. 0.15, -0.37 to 0.67, 
resp; P=0.40), however, total lymphocyte counts increased in SCT over the time from preseason 
to post-camp (P<0.05). Creatinine responses differed between SCT and CON (-0.05, -0.12 to 
0.02 vs. 0.05, -0.03 to 0.12; P=0.05) and potassium decreased a greater extent in SCT (-0.44, -0.6 
to -0.3 vs. -0.2, -0.3 to -0.1; P=0.05) after camp. Complete blood counts in SCT and CON were 
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similar across all measures (P>0.07 for all) when comparing preseason to postseason. The 
adjusted change in sodium (-0.44, -1.22 to 0.35 vs. 1.13, 0.38 to 1.87; P<0.006) and GGT (0.95, -
2.73 to 4.62 vs. 5.32, 1.77 to 8.88; P<0.02) showed significant difference between SCT and 
CON, after season compared to baseline.  CONCLUSION: Despite major hematological 
differences due to SCT, very few changes occurred during the exhaustive, preseason camp and 
regular season at sea level.
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CHAPTER 1. LITERATURE REVIEW 
Introduction 
 The research on sickle cell disease (SCD) in sports has made major progress over the 
years, but still results remain inconclusive about individual’s ability to perform exercise and/or 
sport, and what possible hematological changes occur because of exercise and sport. Sickle cell 
disease is the most common inherited blood disorder amongst people, a mutation in the 
hemoglobin-beta gene found on chromosome 11, causing hemoglobin (Hb) to become abnormal.  
Normal hemoglobin takes the shape of a biconcave disc, while sickle hemoglobin is shaped 
much like a crescent, or sickle. Sickle cell trait (SCT) is passed through generations from 
carriers, prominently of the African-American, Middle Eastern, and Mediterranean descents. 
Sickle cell anemia (SCA) consist of sickle hemoglobin (Hb-S) replacing more than 50% of 
hemoglobin A (Hb-A). On the other hand, is sickle cell trait (SCT) which is known to be milder, 
than anemia, that has less than 50% of Hb-A in the blood. Both sickle hemoglobin and Hb-A are 
both found in the blood of SCA and SCT individuals, but the former has more than a majority of 
Hb-S. The hemoglobin protein in red blood cells (RBC) is the carrier of oxygen through the 
blood. In individuals with SCT, low oxygen levels induce erythrocytes sickling. The sickling 
comes from the mutated beta chains contracting and piling together, causing the shape. Once a 
cell is sickled, it becomes rigid and clumps together, causing the cell to become more fragile. 
Being more fragile increases the erythrocytes probability of being broken more easily, which 
decreases the cell life span by approximately 90%, lasting 10-12 days in the blood compared to 
the 120 days of normal blood cells, in SCA individuals. The fragile and sticky sickle cells alter 
deformability, the ability to conform shape for efficient flow through constricted or dilated 
vessels, giving rise to the probability of blocked blood flow, ultimately, causing hypoxia, and 
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inhibiting oxygen availability to tissues and organs. The inability of a RBC to change shape to 
pass through circulation leads to blood flow resistance, ultimately preventing oxygenated blood 
passing through vessels and bringing oxygen and nutrients to tissues. [1] Rhabdomyolysis, 
splenic infarction, and medullary sickling are three concerns associated with sickle cell, in sport 
and/or exercise. [2] Other factors that are known to increase sickling include, being 
hypohydrated and dehydration, infection, alcohol consumption, high altitudes, extreme 
environmental or body temperatures, acidosis, and strenuous exercise, amongst others. Crises is a 
period of extensive cellular sickling, they can occur from exposure or participation in all the 
scenarios previously stated.  
Exercise and Sickle Cell 
Whether an individual has SCA or SCT, the individuals, coaches and staff need to take 
the necessary precautions of being alert and learning the signs and symptoms. Some signs and 
symptoms include muscle pains, starting in the back and lower body, weakness, undue fatigue, 
breathlessness, muscle cramps, altered mentation. [3-7] Other features of an athlete could include 
the individual slumping to the ground, but still have the ability to speak. [3] Previous research 
has further looked at military, athletes, and individuals during various types of exercise. Many of 
the exercise protocols range from aerobic exercises such as the, 6-minute walk test, cycling 
ergometers, to high intensity sprints, all of which are attempting to emulate the same efforts 
performed during competitions or trainings. [1, 8] How well an individual with SCT is able to 
perform different tasks, associated with exercise, in comparison to an individual without SCT, or 
a control (CON), has shown various different results. In a cycle ergometer protocol, many of the 
results, VO2max (mean±SEM; SCT: 38.6±2.6, CON: 43.3±2.5mL/kg
-1 min-1), maximal heart rate 
(HRmax) (mean±SEM; SCT: 177±6, CON; 177±10 beats/min
-1), maximal power output 
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(mean±SEM; SCT = 283±12, CON: 286±8W), plasma viscosity (mean±SEM at rest; SCT: 
1.69±.04, CON: 1.72±.02mPa/s-1), hematocrit (Hct) (mean±SEM at rest; SCT: 45.75±.69, CON: 
46.21±.44%) and lactate concentration (mean±SEM at rest; SCT: 1.51±.13 , CON: 1.58±.13mM) 
were said to be insignificant or displayed no difference. [8] As stated previously, after maximal 
effort cycling RBC’s continued to have an increased risk of causing blockage, due to an inability 
to change shape to move through vessels. [8] In addition to maximal effort exercise, extended 
periods of strenuous exercise causes a greater increase in blood viscosity, higher RBC lipid 
oxidative stress and higher leukocyte and platelet activation in SCT carriers. [9] In a chronic 
study examining carrier status association with fitness levels, researchers described how SCT 
carriers were at an increased risk of kidney disease, and thrombosis, amongst other 
hematological issues. [10] The increased risk also prompted the authors to consider the carriers’ 
risk for metabolic syndrome. Over a 25-year period, baseline and longitudinal changes of the 136 
SCT carriers showed no significance, for metabolic syndrome or in fitness parameters. Liem et 
al. stated, there was not a difference between SCT status and the incidence of diabetes (n=136 
SCT, n=1859 CON; means; SCT: 0.0, CON: 0.8%; P=.29) or metabolic syndrome (means; SCT: 
2.2, CON: 2.0%; P=.93), among the African American population. [10] In addition to the 
research investigating acute responses to exercise, post-exercise training research had to discern 
crises occurring within hours after exercise. After looking over the blood viscosity, plasma 
viscosity, Hct, deformability/ RBC rigidity, and other hemorheological parameters, the authors 
found higher blood viscosity, at rest (mean±SEM; SCT: 5.01±.29, CON: 4.78±.14mPa·s) and 24 
hours post exercise (mean±SEM; SCT: 4.55±.16, CON: 4.39±.12mPa·s) in SCT individuals 
compared to the healthy trained participants. Hct was found to be lower in the SCT group, and 
RBC rigidity was higher across all three time points, rest, end of maximal exercise and 24h post-
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exercise. [11] Though some studies findings seem to show no significance in the comparison of 
SCT and none SCT individuals exercising, the number of incidents and crises occurring due to 
SCT complications still gives reason to continue researching effects and differences of acute and 
chronic exercise and SCT. 
Sports and Sickle Cell 
 Similar to exercise, sports can vary in the amount of exertion needed in order to perform 
the given task. Over many years, numerous incidents, crises, or death have occurred in sport due 
to SCT. Some of which, happened in the beginning moments of maximal or submaximal efforts, 
or after extended periods of strenuous exertion. [3, 4, 12, 13] For many years, there was 
controversy on whether college athletes should be tested for SCT but following multiple deaths 
in the first decade of the year 2000, rules were changed to require testing, annually, for SCT in 
all athletes whose status was unknown. [6] The first football related collapse occurred on an 
athlete’s first day of practice in two consecutive years. The athlete, Polie Poitier, collapsed after 
running near 700 meters of sprints. After being pronounced dead the following day, the cause 
was said to be acute exertional rhabdomyolysis associated with SCT. Unfortunately, being 
ignorant to signs and symptoms related to a SCT crises, is no longer valid reasoning for 
overexerting an athlete during training. [14] Since then, multiple other occasions in which young 
athletes passed away due to complications associated with SCT occurred. Ereck Plancher, 
Devaughn Darling, Aaron O’Neal, and most notably Dale Lloyd, were some of the few who 
tragically suffered from SCT related deaths while performing their sport. Dale Lloyd’s death was 
responsible for the mandated screening of SCT in all athletes. [14] The National Collegiate 
Athletic Association (NCAA) in April 2010 started the policy to provide necessary education on 
SCT. The new policy demanded all incoming Division I student-athletes be tested for SCT. [6] 
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With the exception of Plancher, Darling, O’Neal, and Lloyd all collapsed during off-season 
workouts, while Plancher’s collapse was post workout, during the off-season. Off-season is the 
time when athletes have been resting from the previous season, followed by workouts and 
trainings in order to help prepare, and better, them for the upcoming season. Off-season training 
can be very tough, depending on the amount of exercise and conditioning an athlete completed 
on their own before the required off-season team workouts. The risk of exertional death in all 
football players with SCT was 37-fold higher, than in athletes without SCT. [12] Hypoxemia, 
acidosis, hyperthermia, and red-cell dehydration are all forces evoked by sustained exercise in 
athletes with sickle cell. [3] As Eichner states, there is a common denominator for sickling 
collapse in athletes with SCT, it is maximal exertion sustained for more than a couple minutes. 
[3] Though sport and exercise are similar, the efforts and exertions given, or expected, during 
competition can be very different. Could research be studying during the wrong seasons, or 
periods? Is there a work to rest ratio that must be implemented? Finding the underlying 
mechanisms that lead to incidents, crises, or deaths due to SCT related complications are 
continually taking steps to improve, but further research is still needed. 
Environmental Effects 
 Though maximal exertion seems to be the leading cause to athletes with SCT collapsing, 
other factors, too, have just as important of a role in causing exertional sickling. The influence of 
environmental factors has not been researched often, but the few that have, found similar results 
of increased sickling due to various weather conditions, in studies wanting to find if there was an 
association of hospital admissions in relation to the environment in individuals with SCD. 
Environmental influences relate to temperatures, humidity, rainfall, wind speed, etc., all of which 
have been researched for extended periods of time. As suspected in a study by Dessap (2014), as 
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the temperatures decreased, the risk of SCD individuals going to the hospital increased. [15] The 
cold temperatures are not likely to cause sickling, but rather a constriction reflex on blood 
vessels, due to the temperature of the skin lowering, which most likely resulted in an obstruction 
in the vessels due to the sickled RBC’s inability to conform their shape. Much like the cooler 
temperatures from the study just mentioned, rainfall, and wind speed emerged as important 
environmental influences to increase SCD related hospitalizations. Higher wind speeds and 
rainfall both can cause a person to feel much colder, which has been suggested as a cause of 
vaso-occlusive pain, or lower thermal stress [16] 
Another very important environmental influence that has the potential to cause sickling of 
RBC’s and possibly lead to other organ damage is altitude. Exercise in high altitude 
environments (above 1100m) has been shown to be correlated to an increased risk for splenic 
infarction in SCT carriers. [9] Altitude changes have a massive effect on partial pressures of an 
individual’s lungs and breathing, whether with sickle cell or having normal hemoglobin. From 
sea level (<500m) to extreme altitudes (>5500m) the partial pressures working to exchange the 
gases, oxygen and carbon dioxide, become affected, by the reduced partial pressures of oxygen 
in the higher altitude. So, as the altitude increases, maximal oxygen uptake begins to decline. 
[17] A former professional football player, suffered life threatening complications from SCT 
while in Denver, Colorado (5280 feet). Ryan Clark was withheld from participating in the game 
due to sudden pains, which came from the blocked vessels induced by exertional sickling. The 
sickled cells prevented the oxygenated blood cells from reaching his spleen, ultimately causing 
splenic infarction which led to the removal of his spleen and gall bladder. [14] Another research 
study showed that extreme altitude also has a detrimental effect on aerobic exercise. During this 
34.1km race, in altitudes of 3800+ meters, athletes with SCT showed significant performance 
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decrements, in comparison to their matched non-SCT runners (means±SD; SCT=52.0±11.1mins 
vs CON=45.2±9.7mins; P<0.01). [18] Knowing all the different environmental factors that have 
a potential effect on sickling of RBC’s, can help individuals understand the necessary 
precautions that need to be taken when preparing, or performing in the various conditions.  
Stressors 
 In life and exercise, other factors can result in stress in individuals with SCT. Some of 
those factors can be, being hypohydrated, in poor physical condition, as well as inflammation or 
oxidative stress, which both have immediate responses to exercise or activity. Staying hydrated 
is a vital part of living, and the inability to maintain fluid balance, prior or during exercise, can 
cause stress on an individual with SCT. Fluids help transport nutrients and remove waste, but 
they can also assist with body temperature regulation. The previous section demonstrated how 
temperature changes can affect circulation, and several studies examined the role hydration has 
in an individual with SCT, euhydrated and hypohydrated, in comparison to CON participants. 
Tripette et al., looked at SCT and non-SCT, in both a dehydrated state and hydrated state and 
examined hemorheological responses after submaximal exercise. In response to exercise, the 
researchers found the plasma viscosity (means±SD; Dehyd: 1.58±.07, 1.68±.18 mPa/s; Hyd: 
1.53±.07, 1.67±.20 mPa/s) increased in SCT athletes, no matter hydration status, in comparison 
to their baseline values. [19] The participants blood viscosity, in both articles, found similar 
results, with SCT athletes having greater blood viscosity in comparison to CON, and the 
dehydrated group of SCT athletes increasing their blood viscosity during recovery or post 
competition. [19, 20] As blood flow becomes slower following exercise, and in comparison, to 
non-SCT at rest, surprisingly RBC rigidity decreased following exercise, without regard to 
hydration. The change, between being hydrated or not, was observed during the 2-hour recovery 
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period, when RBC rigidity greatly increased past initial values, in the dehydrated SCT athletes, 
and the hydrated SCT athletes steadily decreased their RBC rigidity. [19] Despite not knowing 
whether the individuals are euhydrated prior to exercise, making sure SCT individuals have 
water to consume during exercise has shown to benefit blood flow, during and following 
exercise. 
Some of the most harmful effects of sickling include, endothelial dysfunction, inflammation, and 
vaso-occlusion, which all arise from increased oxidative stress. Oxidative stress is the imbalance 
in the making of antioxidants and oxidants. [21] Various articles have found that chronic 
exercise has improved the balance of oxidants and antioxidants, decreasing the oxidative stress. 
In one study that determined whether regular training improves oxidative stress, in untrained and 
trained, SCT and non-SCT, the participants performed incremental maximal exercise on a cycle 
ergometer. Aside from the performance results, SCT and CON show similar maximal aerobic 
power, the trained SCT had higher platelet counts than untrained SCT and CON. Antioxidants 
such as superoxide dismutase (SOD) (means±SD; 3.4±1.4, 8.7±7.7µmol·ml-1·min-1), and nitric 
oxide metabolites (NOx) (means±SD; 19.8±3.1, 28.8±11.4µmol.1
-1) all showed significant 
increases following exercise, compared to baseline, in trained individuals. In addition, 
glutathione peroxidase (GPX), another antioxidant, increased compared to baseline, but without 
regard to Hb or training status. [21] In a different study, the testing protocol called for mild to 
moderate endurance exercise for 20 mins in SCA individuals and non-SCT, CON. Faes et al. 
determined the effects of the exercise protocol on oxidative stress, adhesion and NO 
bioavailability. Though expected, in comparison to the more benign SCT study, the authors 
found differences in performance as well as with oxidative stress, negatively affecting SCA 
individuals. Following exercise, SCA NOx was significantly lower, platelet count, white blood cells, 
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and GPX were all significantly higher, all compared to baseline. [22] Though most of the changes post 
exercise were similar to those in the CON group, the fact that the SCA individual’s baselines values 
varied significantly in nitrotyrosine (means±SD; CON: 57.9±24.2, SCT: 207.9±60.4nmol/l), GPX 
(means±SD; CON: 8.4±4.3, SCT: 11.2±7.7nmol/l/min), ferric reducing antioxidant power (FRAP) 
(means±SD; CON: 1076±207, SCT: 1343±322µmol/l), and NOx (means±SD; CON: 22±10, SCT: 
14.1±8.3µmol/l), showed nonbeneficial to preventing oxidative stress. [22] 
To know that a well hydrated SCT athlete can reduce the potential of sickling RBC’s from blocking 
vessels, by augmenting vasodilation, shows there are still ways to improve the performance and health of 
these individuals. In addition, staying active can also help with maintaining the balance of antioxidants 
and oxidants in response to exercise. Though some results show improvements in the ability of blood to 
flow, or decrease sickling, and damage to organs, other factors such as, pre-exercise hydration, illness, 
climate, exertion, and situational individual responses may still play a role in causing sickling or 
incidence. 
Purpose 
 We explored the biological, physiological, and psychological effects of division I-A 
collegiate level training on individuals with SCT.  In order to examine these relationships, we 
recruited college level athletes with SCT and tested them for hematological changes that 
occurred in a season, from rest (preseason), throughout their season (camp), and at the 
conclusion of their seasons (postseason) in their respective sports.  We hypothesized that, the 
athletes would have minimal differences in ability to perform their necessary task, but we 
expected some hemorheological changes would be more noticeable in the SCT athletes, 
following postseason.  
 
10 
CHAPTER 2. METHODS 
Participants 
 We recruited sixteen (n=8 SCT; n=8 CON) NCAA Division 1 athletes (12 football, 2 
each from women’s soccer and volleyball) with and without SCT.  The SCT athletes were 
position matched with CON, in attempt to match phenotypes and physical training. Athletes were 
recruited by word of mouth and contacted by their athletic trainers. All the athletes were offered 
the informed consent, provided time to review the documents, and signed the content prior to 
baseline testing and their screening data. 
Inclusion/Exclusion Criteria 
 Only active athletes in their respective sports with confirmed SCT were included in the 
study. SCT was determined by their health history provided by the medical staff or athletic 
trainers and confirmed by their baseline laboratory screening. Conversely, the position-matched 
athletes were confirmed to be without SCT, by the staff, and served as the control (CON) group. 
Participants could be excluded if principle investigators deemed necessary due to other medical, 
psychiatric, or behavioral factors that would interfere with study participation or ability to follow 
protocol. 
Study Design 
 Blood chemistry data was collected before (Pre-season), during (Camp), and after (Post-
season) the season, in all sixteen athletes. Any data we collected during Camp was due to the 
occurrence of an “event” with one of the sickle cell athletes. Events were deemed as such by the 
athletic training staff of any incident that resulted in dizziness, extreme fatigue, lethargy, 
cramping, or any other related symptomology due to SCT. Data on the position-matched 
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participant was also collected if an event occurred. In addition, data was collected before, during, 
and after scheduled practices during pre-season camp. Practice data included body weight, urine 
specific gravity and electrolytes, sweat rates, skin and core temperatures, heart rate and heart rate 
variability (HRV), and breathing rate, but we limited the analysis to only hematological data for 
this manuscript. 
Practices, and any other sport related activities done by the athletes, were conducted by their 
respective coaches. Investigators had no influence on the physical activity training, or sport-
specific physical performance testing of the athletes. Environmental conditions were also 
collected to determine possible correlations between weather and athlete’s ability to perform. 
Practices consisted of team warmups and stretching, installation walk-thru, skill drills with their 
position groups, individual, team, and offense vs. defense.  Practices were conducted indoors and 
outdoors. 
Visits/Assessments 
 Pre-season data served as baseline measurements, while follow-up measurements, camp, 
post-season or events, examined chronic changes associated with practice and competitions 
throughout the season. Blood samples from each participant consisted of 10 mL of plasma 
(EDTA) and 10 mL of serum, at each time point and examined at Pennington Biomedical 
Research Center Clinical Laboratory for changes in hemoglobin, complete blood cell counts, 
white blood cell counts, amongst other hematological properties associated with SCT. Additional 
blood samples were collected when medical events occurred and were analyzed for similar 
parameters listed above and for performance enhancing supplements. These outcomes allowed us 
to examine additional unknown interactions that may occur in SCT athletes. 
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Statistical Analysis 
All statistics were performed using JMP version 13.0 statistical software (SAS Institute 
Inc., Cary, NC).  Data analysis followed CONSORT recommendations using General Linear 
Models and repeated measures analysis of variance (RM-ANOVA), co-varied as needed 
depending on normality distributions at baseline. Paired (by position-matched group) and 
independent t-tests were used to compare group differences at each time-point (Pre-season, Post-
camp, and Post-season).  No adjustments for multiple comparisons were used given the pilot 
nature of this study.  In addition, two-way RM-ANOVAs (SCT x time-point) were used to 
determine differences in responses in all hemorheological variables.  Student’s t tests were used 
to determine significant effects when appropriate.  Baseline adjusted change scores (post-camp – 
pre-season; post-season – pre-season) were also presented due to the potential effects of the 
midpoint testing on the RM-ANOVA modeling.  Baseline data were reported as mean±SD and 
baseline adjusted change scores were presented as mean±95%CI.  Significant differences were 
declared at P<0.05. 
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CHAPTER 3. RESULTS 
Table 1. Baseline Participant Characteristics 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
n 12 6 6 - -  
Age (y) 20.3±1.6 19.6±1.9 20.8±1.2 0.22 0.16 0.42 
Weight 
(kg) 
115.7±24.7 117.0±27.9 114.4±23.7 0.86 0.48 0.12 
Height 
(cm) 
189.9±5.1 187.1±5.2 192.6±3.4 0.06 0.07 0.81 
Total Hb 14.6±0.8% 14.8±0.8% 14.4±0.8% 0.47 0.007 0.12 
Hb-A 76.0±20.1% 56.8±0.9% 95.2±0.4% <0.0001 <0.0001 0.47 
Hb-A2 3.13±0.4% 3.5±0.2% 2.8±0.2% 0.0001 0.002 0.69 
Hb-S 19.2±20.1% 38.5±0.9% 0.0% <0.0001 <0.0001 >0.99 
Hb-F 0.4±0.3% 0.4±.0.3% 0.5±0.3% 0.26 0.40 0.21 
Hb-C 0.0 0.0 0.0 - -  
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individuals variability with matched pairs.  Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. 
 
Table 2. Baseline Complete Blood Counts 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Red Blood 
Cells (RBC) 
(x106) 
5.0±0.4 5.2±0.3 4.9±0.4 0.09 0.20 0.29 
Hematocrit 
(Hct) 
42.4±2.0% 43±2.5% 41.8±1.5% 0.36 0.20 0.30 
Mean Cell Vol. 
(MCV) (fL) 
84.5±6.4 82.3±3.4 86.8±8.2 0.24 0.14 0.34 
MCH (pg) 29.1±2.8 28.3±1.2 30.0±3.7 0.31 0.25 0.52 
MCHC (g/dL) 34.4±0.9 34.4±0.5 34.4±1.3 0.98 0.98 0.54 
RDW 13.8±1.1% 14.3±1.0% 13.3±1.0% 0.14 0.09 0.38 
Platelet Count 
(x103) 
232.9±54.2 224.0±67.1 241.8±42.0 0.59 0.62 0.86 
White Blood 
Cell (WBC) 
(x103) 
6.4±1.2 6.7±1.4 6.1±1.0 0.41 0.13 0.17 
Neutrophils 62.2±11% 68.1±9.8% 56.4±9.3% 0.06 0.04 0.44 
Lymphocytes 28.2±9.3% 23.7±7.7% 32.8±9.1% 0.09 0.04 0.32 
Monocytes 7.5±1.9% 6.7±2.5% 8.2±0.8% 0.17 0.15 0.61 
Eosinophils 1.5±1.0% 1.0±0.7% 2.0±1.1% 0.09 0.19 0.31 
Basophils 0.5±0.2% 0.5±0.2% 0.5±0.2% 0.90 0.89 0.73 
Neutrophil # 
(x103) 
4.0±1.3 4.6±1.4 3.5±1.0 0.13 0.005 0.14 
(Table Cont’d.)       
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 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Lymphocytes 
# (x103) 
1.7±0.5 1.5±0.5 2.0±0.5 0.15 0.21 0.76 
 
Monocytes # 
(x103) 
0.5±0.1 0.4±0.2 0.5±0.1 0.51 0.60 0.36 
Eosinophils # 
(x103) 
0.1±0.1 0.1±0.1 0.1±0.1 0.19 0.29 0.41 
Basophils # 
(x103) 
.02±.04 .02±.04 .02±.04 1.00 - 0.03 
Reticulocytes 1.4±0.5% 1.3±0.5% 1.5±0.6% 0.62 0.56 0.50 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. 
 
Table 3. Baseline Blood Chemistries 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Glucose 
(mg/dL) 
87.5±12.6 87.4±11.2 87.7±15 0.97 0.98 0.78 
Sodium 
(mmol/dL) 
136.8±1.3 137.0±1.7 136.6±1.0 0.61 0.69 0.30 
Chloride 
(mmol/dL) 
103.7±1.1 103.5±0.8 104.0±1.4 0.44 0.48 0.83 
Potassium 
(mmol/dL) 
4.5±0.3 4.6±0.4 4.4±0.3 0.56 0.64 0.40 
Carbon 
Dioxide 
(mmol/dL) 
25.2±1.2 25.3±1.7 25.2±0.5 0.82 0.83 0.96 
Uric Acid 
(mg/dL) 
6.6±1.3 7.3±1.4 5.9±0.5 0.04 0.05 0.61 
Calcium 
(mg/dL) 
9.5±0.3 9.5±0.3 9.5±0.2 0.92 0.91 0.64 
CPK (IU/L) 356.0±131.2 386.8±164.6 325.3±92.3 0.44 0.51 0.54 
LDH (IU/L) 225.0±68.9 226.2±93.8 223.8±40.4 0.96 0.97 0.29 
AST (IU/L) 32.5±7.7 32.7±9.5 32.3±6.2 0.94 0.95 0.44 
ALT (IU/L) 26.8±11.8 26.7±10.5 27±14 0.96 0.96 0.69 
ALK 
Phosphatase 
(IU/L) 
82±26.9 85.6±28.9 78.3±26.8 0.66 0.72 0.42 
GGT (IU/L) 18.3±14.7 21.3±14.8 15.3±15.2 0.50 0.53 0.91 
Amylase (U/L) 80.6±26 98.2±26.9 63.0±4.5 0.01 0.02 0.70 
Iron (µg/dL) 101.7±30.7 96.7±16.5 106.7±41.7 0.60 0.47 0.31 
Cholesterol 
(mg/dL) 
171.2±20.8 177.5±26.7 164.8±12.1 0.31 0.34 >0.99 
(Table Cont’d.) 
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 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Triglycerides 
(mg/dL) 
138.4±70.0 133.5±67.6 143.3±78.4 0.82 0.84 0.68 
HDL 
Cholesterol 
(mg/dL) 
56.8±16.9 56.1±19.1 57.5±16.3 0.89 0.90 0.80 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. *insufficient blood samples from 
multiple position-matched participants. 
 
Table 4. Camp Hemoglobin Levels 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Total Hb 14.0±0.7 14.1±0.7 13.9±0.7 0.67 0.18 0.13 
Hb-A 75.9±20.2 56.6±0.3 95.2±0.3 <0.0001 <0.0001 0.35 
Hb-A2 3.1±0.4 3.5±0.1 2.8±0.1 0.0002 0.004 0.54 
Hb-S 19.3±20.2 38.7±0.3 0±0.3 <0.0001 <0.0001 >0.99 
Hb-F 0.4±0.3 0.4±0.1 0.5±0.1 0.27 0.41 0.20 
Hb-C 0 0 0 - - - 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. 
 
 
Baseline Data 
Anthropometric data at baseline are shown in Table 1. The table shows there was no significant 
differences between or within our SCT and CON groups, confirming our position matches to 
being similar. In addition to the anthropometric data, baseline hemoglobin data showed many 
significant differences, also in table 1. Total Hb (within: P=0.007), Hb-A (between: P<0.0001; 
within: P<0.0001), Hb-A2 (between: P=0.0001; within: P=0.002), and Hb-S (between: 
P<0.0001; within: P<0.0001) were all significant, with SCT being higher, lower, higher and 
higher, resp. in comparison to the CON. SCT participant’s basal values for neutrophils 
(68.1±9.8% vs 56.4±9.3%; within P=0.04) and neutrophil number (4.6±1.4x10^3 vs 
3.5±1.0x10^3; within P=0.005) were elevated, and lymphocytes (23.7±7.7% vs 32.8±9.1%; 
within P=0.04) were lower than their CON matches, as shown in Table 2. From Table 3, uric 
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acid (SCT= 7.3±1.4mg/DL vs CON=5.9±0.5mg/DL; between P=0.04, within P=0.05) and 
amylase (SCT=98.2±26.9u/L vs CON=63.0±4.5u/L; between P=0.01, within P=0.02) were the 
only two measures to show significance, as individuals and when looked at as the same person.  
Follow-up Data by Time Point 
Camp 
Table 5. Camp Complete Blood Counts 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Red Blood 
Cells (RBC) 
(x106) 
4.9±0.4 5.0±0.2 4.7±0.5 0.17 
 
0.22 0.75 
Hematocrit 
(Hct)  
40.8±1.9% 41.1±2.3% 40.7±1.6% 0.71 0.47 0.18 
Mean Cell Vol. 
(MCV) (fL) 
85.2±7.0 82.5±2.9 87.9±9.1 0.20 0.12 0.36 
MCH (pg) 29.2±2.8 28.3±1.2 30.1±3.8 0.29 0.24 0.50 
MCHC (g/dL) 34.2±0.7 34.3±0.7 34.2±0.8 0.82 0.83 0.90 
RDW 13.8±1.1% 14.3±0.9% 13.3±1.2% 0.14 0.07 0.30 
Platelet Count 
(x103) 
217.5±42.7 202.5±45.2 232.5±37.8 0.24 0.28 0.92 
White Blood 
Cell (WBC) 
(x103) 
6.9±2.8 6.1±2.1 7.6±3.4 0.37 0.42 0.77 
Neutrophils 56.6±11.1% 54.8±6.2% 58.4±14.9% 0.60 0.55 0.53 
Lymphocytes 32.0±9.7% 33.5±7.4% 30.4±12.1% 0.61 0.50 0.34 
Monocytes 8.6±3.5% 8.2±2.9% 8.9±4.2% 0.73 0.71 0.63 
Eosinophils 3.3±4.2% 5.1±5.5% 1.5±1.1% 0.14 0.15 0.76 
Basophils 0.6±0.2% 0.6±0.2% 0.5±0.2% 0.37 0.52 0.15 
Neutrophil # 
(x103) 
4.1±2.7 3.4±1.2 4.9±3.6 0.35 0.39 0.89 
Lymphocytes 
# (x103) 
2.0±0.6 2.0±0.8 2.1±0.6 0.93 0.87 0.19 
Monocytes # 
(x103) 
0.6±0.3 0.5±0.4 0.6±0.2 0.58 0.52 0.53 
Eosinophils # 
(x103) 
0.13±0.1 0.1±0.1 0.1±0.1 0.80 0.74 0.37 
Basophils # 
(x103) 
0.01±0.03 0.02±0.02 0 0.34 0.36 1.00 
Reticulocytes 1.4±0.6% 1.5±0.5% 1.3±0.6% 0.70 0.74 0.48 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. 
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Table 6. Camp Blood Chemistries 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Glucose 
(mg/dL) 
89.9±17.9 81.8±8.5 98.0±21.9 0.12 0.09 0.44 
Sodium 
(mmol/dL) 
138.2±1.5 138.0±1.5 138.3±1.5 0.71 0.66 0.47 
Chloride 
(mmol/dL) 
104.5±0.9 104.2±0.4 104.8±0.4 0.30 0.43 0.22 
Potassium 
(mmol/dL) 
4.2±0.2 4.1±0.2 4.3±0.2 0.11 0.17 0.66 
Carbon 
Dioxide 
(mmol/dL) 
24.4±1.7 24.4±1.7 24.4±1.8 0.97 0.97 0.99 
Uric Acid 
(mg/dL) 
6.5±1.3 7.2±1.3 5.8±0.7 0.05 0.02 0.25 
Total Protein 
(g/dL) 
7.3±0.4 7.2±0.4 7.4±0.3 0.50 0.46 0.63 
Calcium 
(mg/dL) 
9.3±0.3 9.2±0.4 9.4±0.1 0.36 0.34 0.69 
Phosphorus 
(mg/dL) 
4.4±0.5 4.4±0.5 4.4±0.6 0.96 0.95 0.46 
Total 
Bilirubin 
(mg/dL) 
0.9±0.4 0.9±0.4 0.9±0.4 0.84 0.56 0.14 
CPK (IU/L) 1081.9±531.1 1347.6±477.2 816.3±472.6 0.08 0.17 0.34 
LDH (IU/L) 216.8±45.7 218.8±60.3 214.8±30.8 0.89 0.90 0.66 
AST (IU/L) 39.8±12.6 44.4±12.3 35.1±12.0 0.21 0.35 0.21 
ALT (IU/L) 34.2±11.6 34.7±12.7 33.7±11.6 0.89 0.92 0.25 
ALK 
Phosphatase 
(IU/L) 
84.3±32.2 90.6±35.9 78.0±29.9 0.52 0.57 0.73 
GGT (IU/L) 21.3±12.7 24.5±14.4 18.2±11.1 0.41 0.43 0.99 
Amylase 
(U/L) 
106.3±53.1 130.7±62.5 82.0±29.5 0.12 0.23 0.23 
Iron (µg/dL) 66.8±24.7 65.7±19.5 67.8±30.9 0.89 0.75 0.16 
Cholesterol 
(mg/dL) 
163.7±24.7 168.5±26.8 158.8±23.7 0.52 0.53 0.90 
Triglycerides 
(mg/dL) 
87.8±54.6 100.8±72.0 74.7±31.0 0.43 0.39 0.61 
HDL 
Cholesterol 
(mg/dL) 
54.2±12.8 48.8±13.2 59.5±10.9 0.15 0.10 0.39 
LDL 
Cholesterol 
(mg/dL) 
92.0±27.6 99.6±27.5 84.4±27.9 0.36 0.34 0.68 
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Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. *insufficient blood samples from 
multiple positionn-matched participants. 
 
As shown in table 4, Hb-A (between: P<0.0001; within: P<0.0001), Hb-A2 (between: P=0.0002; 
within: P=0.004), and Hb-S (between: P<0.0001; within: P<0.0001) were the only significant 
hemoglobin measures following camp. Camp activities produced no significant differences in 
any CBC measures for the participants or groups, as shown in Table 5. Table 6 shows the only 
blood chemistry measure, uric acid (SCT=7.2±1.3mg/DL vs CON=5.8±0.7mg/DL; between 
P=0.05, within P=0.02), that showed significance, following camp activities being increased 
compared to CON. 
Post-Season 
Table 7. Postseason Hemoglobin Levels 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Total Hb** 14.6±0.5 14.6±0.5 14.6±0.6 0.94 0.96 0.39 
Hb-A** 75.9±20.3 56.7±0.6 95.1±0.5 <0.0001 <0.0001 0.95 
Hb-A2** 3.2±0.4 3.6±0.2 2.9±0.2 0.004 0.0003 0.91 
Hb-S** 19.2±20.2 38.3±0.7 - <0.0001 <0.0001 >0.99 
Hb-F** 0.5±0.3 0.4±0.2 0.5±0.3 0.60 0.49 0.28 
Hb-C** - - - - - - 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. **missing data from 1 position-
matched with SCT (n=5 CON; n=5 SCT). 
 
Table 8. Postseason Complete Blood Counts 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Red Blood 
Cells (RBC) 
(x106)** 
5.0±0.4 5.2±0.2 4.7±0.4 0.07 0.04 0.95 
Hematocrit 
(Hct)** 
43.3±1.9% 43.4±1.5% 43.1±2.3% 0.82 0.81 0.97 
Mean Cell Vol. 
(MCV) (fL)** 
87.6±5.6 83.6±3.9 91.5±4.0 0.004 0.01 0.25 
(Table Cont’d.)       
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 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
MCH (pg)** 29.6±2.3 28.0±1.5 31.1±1.9 0.02 0.02 0.39 
MCHC (g/dL)** 33.8±0.6 33.6±0.3 33.9±0.7 0.44 0.31 0.30 
RDW** 13.5±1.0% 14.2±0.5% 12.8±0.8% 0.01 0.01 0.36 
Platelet Count 
(x103)** 
240.7±65.0 206.2±50.8 275.2±62.8 0.17 0.09 0.55 
White Blood 
Cell (WBC) 
(x103)** 
6.4±2.1 5.5±1.0 7.2±2.7 0.36 0.24 0.36 
Neutrophils** 47.6±13.5% 50.3±13.8% 45.0±14.4% 0.50 0.57 0.51 
Lymphocytes** 38.3±11.1% 34.2±7.0% 42.4±13.6% 0.16 0.27 0.35 
Monocytes** 9.5±3.0% 9.5±2.6% 9.6±3.6% 0.96 0.97 0.42 
Eosinophils** 3.7±4.9% 4.9±6.9% 2.5±1.3% 0.43 0.46 0.69 
Basophils** 0.9±0.4% 1.0±0.5% 0.8±0.2% 0.44 0.38 0.70 
Neutrophil # 
(x103)** 
3.0±1.2 2.8±1.0 3.2±1.5 0.73 0.65 0.31 
Lymphocytes # 
(x103)** 
2.5±1.5 1.9±0.4 3.1±1.9 0.18 0.19 0.66 
Monocytes # 
(x103)** 
0.6±0.2 0.5±0.1 0.6±0.2 0.25 0.34 0.42 
Eosinophils # 
(x103)** 
0.2±0.2 0.2±0.3 0.2±0.1 0.59 0.68 0.39 
Basophils # 
(x103)**  
0.1±0.1 0.1±0.1 0.1±0.1 >0.99 >0.99 0.27 
Reticulocytes** 1.3±0.5% 1.4±0.5% 1.2±0.6% 0.71 0.69 0.85 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. **missing data from 1 position-
matched with SCT (n=5 CON; n=5 SCT). 
 
Table 9. Postseason Blood Chemistries 
 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Glucose 
(mg/dL)** 
98.6±27.6 90.8±15.4 106.4±36.3 0.49 0.40 0.52 
Sodium 
(mmol/dL)** 
137.4±1.3 136.8±1.3 138.0±1.0 0.11 0.14 0.49 
Chloride 
(mmol/dL)** 
103.2±1.4 103.1±1.6 103.3±1.3 0.87 0.86 0.89 
Potassium 
(mmol/dL)** 
4.2±0.5 4.4±0.7 4.1±0.3 0.47 0.44 0.99 
Carbon 
Dioxide 
(mmol/dL)** 
21.4±3.9 22.4±1.6 20.4±5.4 0.52 0.45 0.61 
Uric Acid 
(mg/dL)** 
6.3±0.8 6.8±1.0 5.8±0.2 0.05 0.04 0.68 
(Table Cont’d.)       
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 All SCT NORM Between    
P-value 
Within        
P-value 
Pair 
Within 
Calcium 
(mg/dL)** 
9.5±0.3 9.4±0.3 9.5±0.2 0.55 0.50 0.68 
CPK (IU/L)** 506.9±287.4 567.3±334.4 446.5±254.7 0.32 0.54 0.26 
LDH (IU/L)** 216.7±70.1 213.2±83.8 220.1±63.2 0.91 0.89 0.50 
AST (IU/L)** 37.3±11.0 35.6±8.6 39.0±13.8 0.60 0.65 0.53 
ALT (IU/L)** 32.0±14.1 28.0±12.7 36.0±15.7 0.41 0.40 0.86 
ALK 
Phosphatase 
(IU/L)** 
84.3±28.9 84.6±34.2 84.0±26.7 0.98 0.98 0.80 
GGT (IU/L)** 19.4±14.7 17.0±3.6 21.8±21.5 0.59 0.64 0.58 
Iron (µg/dL)** 97.8±29.4 110.6±24.8 85.0±30.4 0.05 0.18 0.23 
Cholesterol 
(mg/dL)** 
174.7±23.9 183.6±27.1 165.8±18.7 0.18 0.26 0.41 
HDL 
Cholesterol 
(mg/dL)** 
59.4±14.2 56.0±15.3 62.9±13.9 0.50 0.48 0.97 
Values are mean±SD.  Between analysis for SCT vs. NORM; Within participants analysis 
accounts for individual’s variability with matched pairs. Bold values are considered significant. 
Pair within is the Wald p-value for the random variability. *Insufficient blood samples from 
multiple position-matched participants. **missing data from 1 position-matched with SCT (n=5 
CON; n=5 SCT). 
 
Table 7 displays the Hb-A (between: P<0.0001; within P<0.0001), Hb-A2 (between: P=0.004; 
within P=0.0003) and Hb-S (between: P<0.0001; within: P<0.0001) significance found, 
following the season. The CBC significant measures following the season were in red blood 
count (5.2±0.2x10^6 vs 4.7±0.4x10^6; within P=0.04), mean cell volume (MCV) (83.6±3.9FL 
vs 91.5±4.0FL; between P=0.004, within P=0.01), mean cell hemoglobin (MCH) (28.0±1.5PG vs 
31.1±1.9PG; between P=0.02, within P=0.02), and red cell distribution width (RDW) (14.2±0.5 
vs 12.8±0.8; between P=0.01, within P=0.01), as shown in Table 8. Of the blood chemistries 
from postseason samples, uric acid (SCT=6.8±1.0mg/DL vs CON=5.8±0.2mg/DL; between 
P=0.05. within P=0.04) and iron (SCT=110±24.8ug/DL vs CON 85.0±30.4ug/DL; P=0.05), were 
the only two to display significant increases compared to CON, as shown in table 9. 
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Time Course Data 
Camp 
All CBC measures across time showed no significance (P>0.11 for all). No significance was 
shown for any blood chemistry measures, as well (P>0.08). 
Season 
The significance found across time for the season were the adjusted changes for sodium (-0.44, -
1.22 to 0.35 vs. 1.13, 0.38 to 1.87; P<0.006) and GGT (0.95, -2.73 to 4.62 vs. 5.32, 1.77 to 8.88; 
P<0.02) measures. All CBC measures showed no significance.  
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CHAPTER 4. DISCUSSION 
 The purpose of the study was to explore the biological, physiological, and psychological 
effects of division I-A collegiate level training on individuals with SCT.  We hypothesized 
minimal differences in ability to perform, and some hemorheological changes would be more 
noticeable in the SCT athletes post-camp and post-season. Preseason blood draws exhibited the 
most significance across all three blood panels whereby major alterations in hemoglobin, 
complete blood count and blood chemistries were observed. As expected, hemoglobin panels 
confirmed the SCT status of the players over all three time-points. In addition, some of the 
WBCs, neutrophils, lymphocytes, etc. measures averages were slightly elevated in SCT 
participants, at baseline, as expected. The participants coming back from being off from 
mandatory sport administered activities, led us to assume those baseline differences would be 
seen. In spite of tremendously great weather conditions for the majority of our study, post-camp 
CBC values produced no significant differences.  
The lack of significant differences was shocking, because previous researcher’s findings 
of significant differences in different blood measures, such as leukocyte activation and platelet 
count during or following exercise. [9, 23] The lack of significant difference could be due to the 
well-trained staff or athletes and their awareness or abilities, to know when breaks are necessary. 
The lack of significance could also be due to the low severity of the environment during the 
entire study. Could hotter or colder temperatures have been more of a factor in causing 
complications due to SCT? Following all season activities, a RBC significance was found when 
participants were looked at as being the same. The RBC significance is possibly brought about 
from the strenuous season and needs of the body during season. For these highly trained athletes, 
during season, stroke volumes were probably elevated, for practices and competitions, to 
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increase cardiac outputs, ultimately trying to provide the body with more oxygenated cells to be 
delivered through the body. In addition to the RBC significance, iron was found to be 
significantly higher in SCT at postseason as well. On each protein of the hemoglobin, iron is 
capable of carrying oxygen, which explains the elevated values found between the two measures, 
RBC and iron. In relations to the RBC, red cell distribution width (RDW), mean cell volume 
(MCV) and mean cell hemoglobin (MCH) all showed to be significant as well, most likely due to 
the significant increase of RBC. RDW showed that in the RBC, the sizes of the erythrocytes 
varied greatly. Those cell size differences could be due to the SCT blood disorder and how the 
cells life spans are shorter or sickled, from hypoxia. With shorter cell life span in SCT 
erythrocytes, the question is could the varying sizes of RBC be significantly greater because the 
reduced time to produce more cells in attempts to maintain a certain RBC level? Or, could the 
varying sizes be accounting for the sickled shape cells? Highly correlated to the significance 
found in the RBC, MCV too showed postseason significance differences, with CON being 
higher. With increased RBC in the blood, the volume of the number of cells also should increase, 
but the inverse occurred. With the MCV increased in the CON could the sickled cells be the 
reason we see lower values in the SCT participants. Lastly, the MCH significance is also 
correlated to the significance found in iron and RBC. Though as previously mentioned, if the 
cells are sickled there is less amounts of oxygen able to be carried, which could justify the 
significantly lower MCH in SCT 
During the preseason, levels of amylase showed significance but did not appear 
significant at any other time point. The preseason significance in amylase, could be due to 
possible carbohydrate loading by the players in attempts to have a great amount of energy for the 
first day of activities. A measure that showed significance during all three time-points was uric 
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acid, which has been said to be associated with oxidative stress and shown increased levels 
following exercise. The association to oxidative stress has said to be due to prevention of the 
kidney to clear out uric acid with lactate, that is produce during exertion. [24] The explanation 
for significant values found in our study after camp could be attributed to the kidneys inability to 
filter the blood. With relatively high levels of creatine phosphokinase (CPK) in SCT participants, 
following camp, the blood osmolality could have been high as well adding more to be filtered. In 
addition to CPK breakdown, if the athletes are hypohydrated, blood osmolality can be affected 
negatively leading to high levels of uric acid. An unlikely possibility for the significant uric acid 
values found post-camp and postseason, can stem from a study that found elevated uric acid 
levels, post-exercise, as a sign of hypertension and poor health. [25] With the strains of 
performing football related task, hypertension can occur, the pressure of blood against the 
arterial walls will continually fluctuate. So, the question is whether elevated levels of uric acid 
are an indicator of poor health or a protective antioxidant for oxidative stress, which can be 
investigated further. 
Across time there were no major effects on blood count markers, which proved that there 
was no interaction between the SCT and CON groups. The only significant measures found were 
of blood chemistry measures, sodium and GGT. The sodium difference could be due to the need 
for SCT participants need to stay hydrated, so rather than storing fluids with from high levels of 
salt ingested, they were just drinking larger amounts of water. Inversely, the large difference 
could due to higher sodium intake by the CON participants, like beverages or meals with more 
sodium. The significance found in GGT, a marker of liver function, metabolic syndrome, and 
oxidative stress, could be due to the increased levels of iron and RBC, which has been said to be 
an influencer on elevated GGT levels, when the RBC are damaged. [26] In addition, GGT could 
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have been affected by participants consumption of fluids before and/or during activities. Could 
the significance reduce to be a non-significant difference, later than the 24 hours post blood 
draw? 
Strengths and Weaknesses 
Strengths of this study was the precision of the position-matched participants. The pairs helped 
us to not only compare CON and SCT participants, but to get as close as possible to the same 
height, weights and amounts of work done by each pair. In addition to being close pair matches, 
the variety of positioned participants, helped us to see various task performed, and their effects. 
All twelve participants were highly trained, all year round, which could ultimately be the reason 
for the lack of significance found. Despite a lack of significance, the study took place in a sport 
setting rather than a laboratory. The setting helped us understand additional environmental or 
task specific activities that may influence participants’ hemorheology. The participants overall 
showed great compliance and adherence to the design. The compliance of the athletes also came 
with outstanding support from the athletic training staff and team members in helping with day-
to-day, when needed. Some of the study’s weaknesses include a small sample size, and the 
insufficient data which removed multiple position-matched groups. In the most scientific 
manner, there was an overall lack of “events” that occurred throughout study which restricted 
our ability to determine markers in the blood that may induce an “event”. In this study, post-
camp and postseason blood draws occurred at least 24 hours after the last practice or game, 
thereby limiting our understanding of the acute effects of the activities on hemorheology. Last, 
the environmental stress was lower than typical for this year across all athletes and time-points, 
posing a relative weakness to evaluate the environmental effects in SCT. 
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Conclusion 
 As expected, SCT did show significant differences during the various time-points, but 
many questions and continued research would be able to help identify other influences, such as 
the environment, not being highly trained, etc. that cause complications due to SCT. The study 
only showed significance across time in sodium and GGT, providing us information that these 
highly trained participants, SCT and CON, show individual differences in blood measures but 
their differences are parallel to their position matched partners.   
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APPENDIX. IRB APPROVAL FORMS 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
INFORMED CONSENT 
 
Title of Study: Sickle cell trait in collegiate athletes: effects on mental, physical, and 
emotional resiliency. 
 
We give you this consent form so that you may read about the purpose, risks and 
benefits of this research study. 
 
• The main goal of a research studies is to gain knowledge that may help future 
athletic trainers and coaches make better decisions about appropriate treatment 
for athletes with the sickle cell trait. 
• You have the right to refuse to take part, or agree to take part now and change 
your mind later on. 
• Please review this consent form carefully and ask any questions before you 
make a decision.  
• Your participation is voluntary and will not influence your team standing or your 
practice training.  
• By signing this consent form, you agree to participate in the study as it is 
described.  
 
1- Investigators: 
The following investigator will be available for questions about this study: 
 
 Principal Investigator:    Neil M. Johannsen, Ph.D. 
           Phone: 225-578-5314 
           Email:njohan1@lsu.edu 
           
 Co-Investigators:        Jack Marucci 
 Phone: 225-578-2451 
 Email: jmarucc@lsu.edu 
       Shelly Mullenix 
Phone: 225-578-8642 
Email: smulle1@lsu.edu 
      Timothy S. Church, M.D., M.P.H., Ph.D. 
 Email: tim.church@pbrc.edu  
      Brian Harrell, M.D. 
Phone: 337-292-0431 
Email: brian.harrell@brgeneral.org 
      Guillaume Spielmann, Ph.D. 
     Email: gsspielmann@lsu.edu 
      Brian Irving, Ph.D. 
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     Email: brianirving@lsu.edu 
          Jennifer Rood, Ph.D. 
     Email: Jennifer.rood@pbrc.edu 
           
      Tiffany Stewart, Ph.D. 
       Email: tiffany.stewart@pbrc.edu  
          Ray Castle, Ph.D., ATC, LAT 
     Email: rcastl1@lsu.edu 
          LeKeitha Poole, Ph.D. 
     Email: lpoole2@lsu.edu 
           
Neil Johannsen, Ph.D. directs this study. We expect about 30 athletes will be enrolled in 
this study per year; ~15 with sickle cell trait and ~15 position matched controls.  The 
study will take place over a period of about 1 year for each athlete and may include 
athletes from multiple sports. 
 
2- Performance Site: 
This study will take place at Louisiana State University-Baton Rouge Campus. 
 
3- Purpose of the Study: 
This study is designed to explore the biological, physiological, and psychological effects 
of elite level training on individuals with the sickle cell trait. In addition, we aim to 
determine mediating factors affect your ability to perform in your sport including 
hydration status, body temperature, and cardiovascular responses. 
 
4- Participant Inclusion: 
Participants will include athletes form Louisiana State University who are active in their 
sport during the season. Athletes with confirmed sickle cell trait will be included in this 
study as determined by the health history provided by the LSU medical staff or trainers.  
Other athletes matched for sport position (ex. linebacker) will be serve as the study 
control group.   
 
You are eligible for this study if you are: 
• An athlete at Louisiana State University 
• Capable and willing to give written informed consent, understand exclusion 
criteria 
• Cleared by a Louisiana State University physician to participate in your given 
sport. 
 
You are NOT eligible for this study if you have any conditions the Louisiana State 
University physician regards as being too risky to participate in your sport.  Additionally, 
you can be excluded for any other medical, psychiatric or behavioral factors that in the 
judgment of the Principle Investigator may interfere with study participation or the ability 
to follow the protocol.   
The investigators of this study will have access to the data collected under the 
supervision of your physician during your exam to determine final study inclusion. 
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5-Study Procedures: 
The study for which you are volunteering could last an entire competitive season (1 
year).  The study will include 4 time points for data collection: 
 
1. Pre-Seaseon 
2. Pre-Competition Season 
3. Post-Competition Season 
4. Before, During, and/or After Practice 
 
Summary of Visit Schedule 
Procedure 
Pre-
season 
Pre-
competition 
Post-
competition 
Practice 
Informed 
Consent 
X    
Screening X    
Blood 
Samples 
X X X X 
Body Weight X   X 
Physiological 
Monitoring 
X X X X 
Urine 
Samples 
   X 
Sweat 
Samples 
   X 
Fluid Intake    X 
Body 
Temperatures 
   X 
Psychological 
Data 
X X X X 
 
Screening Visit  
At this visit, or during multiple visits, you will undergo your standard tests as part of 
being an athlete in your sport.  This visit may or may not occur before you were offered 
to participate in the study.  Study personnel will examine and record some of the 
information collected during your physical exam and pre-practice testing.  The following 
information and procedures will be used as part of this study:  
o Height and weight 
o Medical history and medication use 
o Blood pressure and heart rate – by a cuff placed around your arm and 
pulse 
o Body composition 
Version Date 07/24/2017  Volunteer’s initials__________ 
31 
 
If you choose not to participate in this study, none of your data collected will be used by 
the study investigators for this research. 
 
Study Visits 
You will have assessments taken Pre-season, Pre-competition, and Post-Competition.  
These assessments will include physiological and psychological monitoring and blood.  
Pre-season data collected will serve as the baseline measurements.  The follow-up 
measurements will examine the chronic changes associated with practice and 
competitive seasons throughout the year.   
o Psychological Data - Sleep quality questionnaire, sources/symptoms of 
psychological well-being, and activation state  
o Blood Collection - a small amount of blood will be taken from an arm vein 
to look for known markers of sickle cell changes related to training and 
stress.  About 20 mL of blood (2 Tablespoons) will be drawn at each of the 
3 visits. 
o Physiological Monitoring - A monitor will be worn around your chest.  The 
monitor can assess heart rate and the variability in your heart rate, a 
measure of heart health. 
 
Practice – before, during, and/or after 
In addition to the periodic study visits listed above, you will be monitored before, during, 
and after practice.  The practice will be conducted under the direction of coaches.  
Study investigators will have no influence on the physical activity training and the 
Louisiana State University Athletic Department medical staff will be present throughout 
the practices.  However, we will monitor and collect observational data.  Practice 
assessments will include body weight, physiological monitoring, fluid intake, body 
temperatures, sweat collection, and urine collection.  
o Body weight 
o Physiological Monitoring - A monitor will be worn around your chest.  The 
monitor can assess physical activity level, heart rate, breathing rate, and 
GPS data (distance and speed running).   
o Fluid intake – the amount and type of fluid you ingest prior to and during 
practice may be recorded to use in together with body weight to estimate 
sweat rate. 
o Body temperature – skin temperature will be taken by an infrared 
thermometer, core temperature will be assessed by an ingestible pill. 
o Sweat patch application and removal – An adhesive patch with an 
absorbent cotton material is placed on the body and remains during 
practice.  The absorbent material will be weighed before application and 
after removal to estimate sweat rate.  The sweat will be analyzed for. 
o Urine sample – a small sample of urine will be provided and analyzed for 
color, specific gravity, osmolality, and sodium, potassium, and chloride. 
In addition to these measures, other data collected by the Louisiana State University 
Athletic Department medical staff or team physicians may be used as data in this study.  
All additional measurements will be performed if the Louisiana State University Athletic 
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Department medical staff or study physicians deem it is medically necessary.  These 
measurements could include urine and blood chemistries, psychological data, body 
temperature, hard outcome data (for example - incidence of heat-related illness, muscle 
cramps, injuries, concussion), and other data collected during practice from existing 
practices by the LSU teams that may be related to the sickle cell trait.  In addition, in 
these cases, urine and/or blood samples may be used to determine the use of 
performance enhancing supplements.  If you are volunteering as a control participant, 
the additional measurements will also be conducted if medical “event” occurs in your 
pair matched sickle cell trait participant. 
o Blood Collection - a small amount of blood will be taken from an arm vein 
to look for known markers of sickle cell changes related to training and 
stress.  About 20 mL of blood (2 Tablespoons) will be drawn. 
o Urine Collection - Urine sample – a small sample of urine will be provided 
and analyzed for color, specific gravity, osmolality, and sodium, 
potassium, and chloride. 
o Psychological Data - Sleep quality questionnaire, sources/symptoms of 
psychological well-being, and activation state  
o Outcome data – hard outcomes, such as muscle cramping, dehydration 
and IV infusion, hyper- or hypothermia, injuries, concussion, and others, 
may be collected as part of the study. 
o Other data – data collected during practice from existing measures may 
be used as part of this study.  This data will be related to the ability to 
assess or predict future heat-related illness or muscle cramping. 
 
6- Risks/Discomforts: 
Sweat Collection: There are no risks associated with this test.  There is a small 
possibility there may be some redness or irritation if you happen to be allergic to the 
adhesive on the collection patches. 
 
Core temperature: There are no risks associated with this test.  The pills provided to the 
participants will be unused and sterile prior to use. The pills contain metal; participants 
who ingest the pills should not undergo an MRI scan until the pill has passed in the 
feces (~24-48 hours).  The LSU Athletic Department medical staff and team physicians 
will be notified who has ingested the pills in order to avoid the risk of MRI. In the event 
that an injury occurs that requires transport to another facility for evaluation using an 
MRI, a note will be sent with the participant informing the staff to use an alternative 
method, other than an MRI, for diagnostic purposes. 
 
 
Heart rate monitor:  There are no known risks associated with the monitor. 
 
Blood draws: Trained and medically certified personnel will and draw your blood.  The 
training for the personnel may include physician monitored and/or phlebotomy 
certifications.  There may be minimal discomfort and bruising and/or bleeding where the 
needle is inserted for finger prick blood sampling.  There is a possibility of pain, bruising, 
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and/or infection at the site of the needle insertion.  Aseptic (sterile) technique and 
trained personnel minimize this risk. 
 
Loss of Confidentiality:  Completing questionnaires may result in a breach in 
confidentiality of personal data.  Participants will be assigned ID numbers and 
information that could identify a participant will not appear in publications.  However, the 
data collected as part of this observational study can be shared with your sport-specific 
coaches and athletic trainers. 
 
Unknown risks:  In addition to the risk listed above, you may experience a previously 
unknown risk or side effect. 
 
7- Benefits: 
We cannot promise any benefits from your being in the study.  However, possible 
benefits include: 
• Information about your general health 
• Information regarding your body’s response to exercise in an outdoor 
environment 
 
8-Alternatives to Participation: 
There are no alternatives to the study described in this consent.  You have the choice at 
any time not to participate in this research study.  If you choose not to participate, any 
benefits to which you are entitled will not be affected in any way. 
 
9- Injury/Illness or Questions: 
If you have any questions about your rights as a research volunteer, you should call 
Dennis K. Landin, Ed.D., Institutional Review Board Office at 225-578-8692.  If you 
have any questions about the research study, contact Neil Johannsen, Ph.D. at 225-
578-5314 during regular working hours.  If you believe you have a research-related 
injury or medical illness, contact Louisiana State University Athletic Department medical 
staff or team physician. 
 
10-Privacy: 
Every effort will be made to maintain the confidentiality of your study records.  Results 
of the study may be published; however, we will keep your name and other identifying 
information private.  Other than as set forth above, your identity will remain confidential 
unless disclosure is required by law.  
 
 
11-Early Study Withdrawal: 
Neil Johannsen, Ph.D. can withdraw you from the study for any reason or for no reason.  
You may withdraw from the study at any time without penalty.  Possible reasons for 
withdrawal include injury, the presence of an old or existing injury that may be deemed 
risky, sufficient medical history deemed too risky for testing. 
12-Additional Information: 
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During the course of this study there may be new findings from this or other research 
that may affect your willingness to continue participation.  Information concerning any 
such new findings will be provided to you.  
 
13-Charges for Participation: 
None 
 
14-Payments for Participation: 
You will be compensated for your time and the procedures involved with this study.  
Specifically, you will be compensated $25 for each blood draw/laboratory visit for a total 
of $75 if you complete the study.  In addition, if you are required to have additional 
blood drawn (separate from normal athletic or medical training purposes) due to a 
medical event during practice, you will be compensated $25 for each event.  The 
monies will be provided in check form soon after each visit or event. 
 
15- Compensation for study-related injury or medical illness: 
No form of compensation for medical treatment or for other damages (i.e., lost wages, 
time lost from work, etc.) is available from Louisiana State University.  In the event of 
injury or medical illness resulting from the research procedures in which you participate, 
you will be referred to a treatment facility.  Medical treatment may be provided at your 
own expense or at the expense of your health care insurer (e.g., Medicare, Medicaid, 
Blue Cross-Blue Shield, Dental Insurer, etc.), which may or may not provide coverage. 
 
 
16- Signatures:  
The study has been discussed with me and all my questions have been answered.  I 
understand that additional questions regarding the study should be directed to the study 
investigators.  I agree with the terms above and acknowledge that I have been given a 
copy of the consent form. 
 
 
 
       
Printed Name of Volunteer 
 
__________________________________                             _____________ 
Signature of Volunteer                Date 
                                                               
 
__________________________________ 
Date of Birth of Volunteer 
 
__________________________________________             _____________ 
Signature of Person Administering Informed Consent             Date                                                   
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Neil M. Johannsen, Ph.D. 
Principal Investigator  
 
17- Tissue/Specimen Storage for Future Research or Use 
 
Biospecimens for future research: 
You are being asked to allow some of your blood to be stored and used for research at 
a later time. These bodily materials are called biospecimens. The donation of 
biospecimens in this study is optional. No matter what you decide to do, it will not affect 
your study participation. You will still be allowed to take part in the study even if you 
don't want your specimens to be collected and used for future research. Some 
biospecimen samples will be stored and used for the study and other biospecimen 
samples will be stored for future studies. The collection of samples may give scientists 
valuable research material that can help them to develop new diagnostic tests, new 
treatments, and new ways to prevent diseases. If you agree to have your samples 
stored, you can change your mind up until the end of the study. 
 
The samples will be stored indefinitely. If you agree to donate your samples, they may 
be given to other investigators for future research as well. The future research may take 
place at Louisiana State University and may involve Louisiana State University 
Researchers in this study. The future research may not take place at Louisiana State 
University and may not be reviewed by Louisiana State University's Institutional Review 
Board. For privacy and confidentiality, your biospecimens will be labeled with a unique 
series of letters and numbers. Louisiana State University will store your biospecimens 
with this unique identifier and the minimum number of personal identifiers to meet 
laboratory standards. The research done with your specimens may help to develop new 
products in the future, or may be used to establish a cell line or test that could be 
patented or licensed. You will not receive any financial compensation for any patents, 
inventions or licenses developed from this research. 
 
Making your choice about future research:  
Please read about each biospecimen below. It is your choice which samples will be 
collected, stored and used for future research for this study or future studies. After 
reading about each biospecimen below, sign your name next to "Yes" or "No" to show 
your choice about the collections for this research study and for future research studies.  
 
Blood  
If you give permission, approximately 1 tablespoon of blood will be stored by this study. 
Your stored samples may be tested at Louisiana State University or other locations 
used in future research.  
Do you give permission for your blood to be collected and used in future research by 
this study? 
 
Yes, I give permission  
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                                                                             SIGNATURE 
 
No, I do not give permission 
                                                                             SIGNATURE 
Urine  
If you give permission, approximately 1 tablespoon of urine will be stored by this study. 
Your stored samples may be tested at Louisiana State University or other locations 
used in future research.  
 
Do you give permission for your blood to be collected and used in future research by 
this study? 
 
Yes, I give permission  
                                                                             SIGNATURE 
 
No, I do not give permission 
                                                                             SIGNATURE 
 
 
If you decide you would like to withdraw your consent to use your samples, you will be 
able to do so until the study ends. After the study ends, you will not be able to withdraw 
your consent to use your samples because investigators will not know which one is 
yours. You must provide a written request to have your samples destroyed.  
 
For destruction of your samples, you can contact the Principal Investigator at: 
 
 
Neil Johannsen, PhD 
Louisiana State University 
112 Huey P. Long Fieldhouse 
Baton Rouge, LA 70803 
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VITA 
 Michael E. Owens was born in Carrollton, Georgia, in 1992, but was raised in Houston 
Texas. He has always been interested in sports, but more importantly wanting to be involved in 
them, due to his desire stay active and compete. After participating in college football, during his 
first few years of undergraduate studies, he knew helping others, by maximizing and coaching 
sports performance, was what he really wanted to accomplish. Following his break from 
obtaining his bachelors in 2015, he ultimately decided to return to school for his masters, in 
search of greater knowledge, and opportunities to get closer to his goals.   
